A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00367445

Enrollment

Registered

2006-08-22

Start date

2006-09-30

Completion date

2007-02-28

Last updated

2008-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus

Interventions

DRUGInhaled Human Insulin (Exubera)

DRUGInsulin Glargine (Lantus)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diabetes mellitus Type 2

Exclusion criteria

* Severe Asthma, severe COPD * Smoking

Design outcomes

Primary

Measure	Time frame
Variability of blood glucose over a period of 72 hours	—

Secondary

Measure	Time frame
Insulin pharmacokinetics	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026